Patient-based strategy for systemic treatment of metastatic renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 4, 2010, Pages 585-596

  Kirchner, Hartmut ^a   Strumberg, Dirk ^b   Bahl, Amit ^c   Overkamp, Friedrich ^d  

^a Krankenhaus Siloah   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^d Praxis und Tagesklinik für Internistische Onkologie und Hämatologie   (Germany)

Author keywords

MTOR inhibitor; Patient based approach; Renal cell carcinoma; Sequence therapy; Targeted therapy; Treatment algorithm; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AXITINIB; BAY 73 4506; BEVACIZUMAB; EVEROLIMUS; FLUOROURACIL; INTERLEUKIN 12; PAZOPANIB; PLACEBO; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ALGORITHM; ANEMIA; ASTHENIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG MEGADOSE; DRUG PROTEIN BINDING; EVIDENCE BASED MEDICINE; FATIGUE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INFECTION; KIDNEY CARCINOMA; LIVER TOXICITY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PATIENT CARE; PNEUMONIA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMATITIS; THYROID DISEASE; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS; QUALITY OF LIFE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77951226719     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.25     Document Type: Review

References (95)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2009. CA Cancer J. Clin. 59, 225-249 (2009).
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477-2490 (2005).
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163, 408-417 (2000). (Pubitemid 30060482)
4. Rini BI, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress? Oncology 22, 388-396 (2008).
5. Djulbegovic B, Loughran TP, Hornung C et al. The quality of medical evidence in hematology-oncology. Am. J. Med. 106, 198-205 (1999). (Pubitemid 29115961)
6. Kirchner H, Heinzer H, Roigas J, Overkamp F. Differenzialtherapie beim metastasierenden Nierenzellkarzinom. Der Onkologe 14, 191-197 (2008).
7. Coppin C, Porszolt F, Autenrieth M et al. Immunotherapy for advanced renal cell cancer (Review). Cochrane Database Syst. Rev. CD001425 (2005).
8. Atzpodien J, Kirchner H, Jonas U et al. Interleukin-2- and interferon a-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J. Clin. Oncol. 22, 1188-1194 (2004). (Pubitemid 41079830)
9. Atzpodien J, Reitz M. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-a and s.c. interleukin-2. Cancer Biother. Radiopharm. 20, 410-416 (2005). (Pubitemid 41216105)
10. Bordin V, Giani L, Meregalli S et al. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients. Urol. Int. 64, 3-8 (2000). (Pubitemid 30224033)
11. Escudier B, Chevreau C, Lasset C et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J. Clin. Oncol. 17, 2039-2043 (1999). (Pubitemid 29318832)
12. Gore ME. Interferon-a (IFN), interleukin-2 (IL2) and 5-fluorouracil (5FU) vs IFN alone in patients with metastatic renal cell carcinoma (mRCC): results of the randomised MRC/EORTC RE04 trial. J. Clin. Oncol. 26, (2008) (Abstract 5039a).
13. Escudier B, Pluzanska A, Koralewski P et al. Bevacuzimab plus interferon a-2a for treatment of metastastic renal cell carcinoma: survival and biomarker analysis. Lancet 370, 2103-2111 (2007).
14. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579-591 (2008).
15. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 672-682 (2002).
16. Wilhelm SM, Carter C, Tang L et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004). (Pubitemid 39331023)
17. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007). (Pubitemid 46089673)
18. Bukowski RM, Eisen T, Szczyklik C et al. Final results of the randomized Phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J. Clin. Oncol. 25 (2007) (Abstract 5023a).
19. Szczylik C, Demkow T, Staehler M et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J. Clin. Oncol. 25 (2007) (Abstract 5025a).
20. Jonasch E, Corn P, Ashe RG et al. Randomized Phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25 (2007) (Abstract 5104a).
21. Knox JJ, Figlin RA, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCSS) expanded access trial in North America: safety and efficacy. J. Clin. Oncol. 25 (2007) (Abstract 5011a).
22. Beck J, Bajetta E, Escudier B et al. A large open-label, non-comparative, Phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Eur. J. Cancer Suppl. 5, 4506 (2007).
23. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006). (Pubitemid 46630489)
24. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
25. Motzer RJ, Figlin RA, Hutson TE et al. Sunitinib versus interferon-a (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J. Clin. Oncol. 25 (2007) (Abstract 5024).
26. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN)-a as first-line treatment of metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 26 (2008) (Abstract 5024).
27. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. DOI: 10.1200/JCO.2009.23.9764 (2010) (Epub ahead of print).
28. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003). (Pubitemid 36910021)
29. Escudier B, Bellmunt J, Negrier S et al. Final results of the Phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC). 2009 ASCO Annual Meeting; May 29-June 2; Orlando, FL. J. Clin. Oncol. 27(Suppl.) 15s (2009) (Abstract 5020a).
30. Rini BI, Halabi S, Rosenberg JE et al. CALGB 90206: a Phase III trial of bevacizumab plus interferon-a versus interferon-a monotherapy in metastatic renal cell carcinoma. 2009 ASCO Annual Meeting; May 29-June 2; Orlando, FL. J. Clin. Oncol. 27(Suppl.) 15s (2009) (Abstract 5019a).
31. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999). (Pubitemid 29368255)
32. Motzer RJ, Bacik J, Murphy BA et al. Interferon-a as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002). (Pubitemid 34032623)
33. Mekhail TM, Abou-Jawde RM, BouMerhi G et al. Validation and extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005).
34. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon a or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007). (Pubitemid 46849157)
35. Motzer R, Escudier B, Oudard S et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-III study. J. Clin. Oncol. 26, (2008) (Abstract LBA5026).
36. Motzer R, Escudier B, Oudard S et al. Efficacy of everolimus in adavanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008).
37. Escudier B, Ravaud A, Oudard S et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma. Ann. Oncol. 19, 72O (2008).
38. Sternberg CN, Szczylik C, Lee E et al. A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. 27(Suppl.), 15s (2009) (Abstract 5021a).
39. Dutcher JP, Wilding G, Hudes GR et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J. Clin. Oncol. 26, 5127 (2008) (Abstract 5127).
40. Hutson TE, Davis ID, Machiels JH et al. Biomarker analysis and final efficacy and safety results of a Phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J. Clin. Oncol. 26, (2008) (Abstract 5046).
41. Witteles RM, Telli ML, Fisher GA et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. J. Clin. Oncol. 26, (2008) (Abstract 9597).
42. Clement P, Wolter P, Stefan C et al. Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib. J. Clin. Oncol. 26, (2008) (Abstract 16145).
43. Wolter P, Stefan C, Decallonne B et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br. J. Cancer 99, 448-454 (2008).
44. Billemont B, Rixe O, Meric JB et al. Renal safety of sunitinib treatment: a prospective study for patients (pts) with metastatic renal cell carcinoma (mRCC). Ann. Oncol. 19, E01a (2008).
45. De Souza PL, Radulovic S, Beck J et al. Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-a. J. Clin. Oncol. 26, (2008) (Abstract 5116).
46. Negrier S. Temsirolimus in metastatic renal cell carcinoma. Ann. Oncol. 19, 1369-1370 (2008).
47. Bellmunt J, Szczylik C, Feingold J et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann. Oncol. 19, 1387-1392 (2008).
48. Bhojani N, Jeldres C, Patard JJ et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur. Urol. 53, 917-930 (2008).
49. Wood L, Bukowski RM, Dreicer R et al. Temsirolimus (TEM) in metastatic renal cell carcinoma (mRCC): safety and efficacy in patients (pts) previously treated with VEGF-targeted therapy. J. Clin. Oncol. 26, (2008) (Abstract 16067a).
50. Bajetta E, Ravaud A, Bracarda S et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-a2a (IFN) in patients (pts) ≥ 65 years with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 26, (2008) (Abstract 5095).
51. Porta C, Bracarda S, Beck J et al. Efficacy and safety of sorafenib in elderly pts: results from a large open-label, non-comparative Phase III study of sorafenib in European pts with advanced RCC (EU-ARCCS). Ann. Oncol. 19 (2008) (Abstract 596P).
52. Bukowski RM, Stadler WM, Figlin RA et al. Safety and efficacy of sorafenib in elderly patients (pts) ≥ 65 years: a subset analysis from the advanced renal cell carcinoma sorafenib (ARCSS) expanded access program in North America. J. Clin. Oncol. 26 (2008) (Abstract 5045).
53. Plantade A, Choueiri T, Escudier B et al. Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinsase inhibitors. J. Clin. Oncol. 25 (2007) (Abstract 5037).
54. Gore Me, Porta C, Oudard S et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J. Clin. Oncol. 25 (2007) (Abstract 5010).
55. Stadler WM, Figlin RA, Ernstoff MS et al. The advanced renal cell carcinoma sorafenib (ARCSS) expanded access trial: safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC). J. Clin. Oncol. 25 (2007) (Abstract 5036).
56. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26, 127-131 (2008).
57. Plimack ER, Jonasch E, Bekele BN et al. Sunitinib in non-clear cell renal carcinoma (ncc-RCC): a Phase II study. J. Clin. Oncol. 26 (2008) (Abstract 5112).
58. Strumberg D. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. J. Clin. Oncol. 26, 3469-3471 (2008).
59. Schouten LJ, Rutten J, Huveneers HA et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94, 2698-2705 (2002). (Pubitemid 34478086)
60. Henderson CA, Bukowski RM, Stadler WM et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J. Clin. Oncol. 25(18), (2007) (Abstract 15506).
61. Hariharan S, Szczyklik C, Porta C et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (METS): data from an expanded access trial. J. Clin. Oncol. 26 (2008) (Abstract 5094).
62. Massard C, Zonierek J, Laplanche A et al. Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a Phase III trial of sorafenib, an oral multi-kinase inhibitor. Ann. Oncol. 17 (2006) (Abstract 454P).
63. Helgason HH, Mallo HA, Droogendijk H et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J. Clin. Oncol. 26, 152-154 (2008).
64. Rini BI. Clinical prognostic and predictive markers for metastatic RCC therapeutic choices. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
65. Rathmell WK, Stadler WM, Rini BI. Rational therapeutic choices and strategies for patients with metastatic renal cancer. Am. Soc. Clin. Oncol. Ed. Book 192-198 (2008).
66. Kirkali Z. Will we be able to 'cure' metastatic renal cell carcinoma like we cure testicular tumours? Eur. Urol. 54, 712-714 (2008).
67. Bellmunt J, Mulders P, Szczylik C et al. Defining a new patient-focused treatment approach to renal cell carcinoma (RCC). Ann. Oncol. 19 (2008) (Abstract 612P).
68. Gore M. What are the problems that are to be solved in the future? Presented at: ESMO Annual Meeting. Stockholm, Sweden, 12-16 September (2008).
69. Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal carcinoma. J. Urol. 182, 29-34 (2009).
70. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115(1), 61-67 (2009).
71. Eichelberg C, Heuer R, Chun FK et al. Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. Urol. 54, 1373-1378 (2008).
72. Tamaskar A, Garcia JA, Elson P et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J. Urol. 179, 81-86 (2008). (Pubitemid 350216728)
73. Choueiri TK, Brick AJ, McDermott S et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC). Ann. Oncol. 19(Suppl. 8), (2008) (Abstract 593P).
74. Porta C, Procopio G, Sabbatini R et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur. Urol. Suppl. 8(4), 183(252) (2009).
75. Vickers MM, Choueiri TK, Percy A et al. Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): what next? J. Clin. Oncol. 27(Suppl.), 15s (2009) (Abstract 5098a).
76. Shepard DR, Rini BI, Garcia JA et al. A multicenter prospective trial of sorafenib in patients with metastatic clear cell carcinoma refractory to prior sunitinib and bevacizumab. J. Clin. Oncol. 26 (2008) (Abstract 5123a).
77. Van der Veeldt AAM, Boven E, Helgason HH et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br. J. Cancer 99, 259-265 (2008).
78. Melichar B, Koralewski P, Pluzanska A et al. First-line bevacizumab improves progression-free survival with lower doses of interferon a2a in the treatment of patients with metastastic renal cell carcinoma (AVOREN). Eur. J. Cancer Suppl. 5, 304-304 (2007).
79. Dutcher J, Szczylik C, Tannir N et al. Correlation of survival with tumor histology, age, and prognostic-risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon a. J. Clin. Oncol. 25 (2007) (Abstract 5033a).
80. Richter S, Pfister D, Thüer D et al. Second line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 31 (2008) (Abstract V684a).
81. Feldman DR, Ginsberg MS, Baum M et al. Phase I trial of bevacizumab plus sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26 (2008) (Abstract 5100a).
82. Fischer P, Patel P, Carducci MA et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. J. Clin. Oncol. 26, (2008) (Abstract 16020a).
83. Whorf RC, Hainsworth JD, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol. 26 (2008) (Abstract 5010a).
84. Rosenberg JE, Weinberg VK, Claros C et al. Phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma. J. Clin. Oncol. 26 (2008) (Abstract 5109a).
85. Giessinger S, Amato RJ, Jac J et al. A Phase I study with a daily regimen of the mTOR inhibitor RAD001 (everolimus) plus sorafenib for patients with metastatic renal cell cancer (mRCC). J. Clin. Oncol. 26 (2008) (Abstract 14603a).
86. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26, 3709-3714 (2008).
87. Sosman JA, Flaherty KT, Atkins MB et al. Final results of a Phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer. J. Clin. Oncol. 26 (2008) (Abstract 5011a).
88. Merchan JR, Liu G, Fitch T et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J. Clin. Oncol. 25 (2007) (Abstract 5034a).
89. Brunello A, Sacco C, Barile C et al. Sunitinib in elderly patients (>=70 years) with metatsatic renal cell carcinoma (mRCC): multicenter analysis of tolerability and efficacy. Ann. Oncol. 19 (2008) (Abstract 657P).
90. Bokemeyer C, Porta C, Beck J et al. Efficacy and safety of sorafenib in pts with brain and bone metastases: Results from a large openlabel, non-comparative Phase III study of sorafenib in European pts with advanced rcc (EU-ARCCS). Ann. Oncol. 19 (2008) (Abstract 595P).
91. Eisen T, Beck J, Procopio G et al. Large open label, non-comparative Phase III study of sorafenib in European pts with advanced RCC (EU-ARCCS): subgroup analysis of pts with and without baseline clinical cardiovascular diseases (CCD). Ann. Oncol. 19 (2008) (Abstract 602P).
92. Tolcher A, Appleman L, Mita A et al. Effect of sorafenib treatment on left ventricular ejection fraction in cancer patients: an open-label, Phase I study. Ann. Oncol. 19 (2008) (Abstract 552P).
93. Snow H, Brueckner A, Gelder M et al. Sorafenib is not associated with a high incidence of cardiovascular events in many tumor types. Ann. Oncol. 19 (2008) (Abstract 553P).
94. Zimmermann K, Schmittel A, Steiner U et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76(5), 350-354 (2009).
95. Patnaik A, Ricart A, Cooper J et al. A Phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J. Clin. Oncol. 25 (2007) (Abstract 3512a).